Thromboprophylaxis in cancer utpatients

Blood

Volumn 111, Issue 10, 2008, Pages 4833-

  Doggen, Carine J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

BODY MASS; BRAIN TUMOR; CANCER PATIENT; DISEASE ASSOCIATION; FEBRILE NEUTROPENIA; HUMAN; LEUKOCYTE COUNT; MORBIDITY; MORTALITY; NEOPLASM; NOTE; OUTPATIENT; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; THROMBOCYTE COUNT; VEIN THROMBOSIS;

EID: 61849087496     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-137760     Document Type: Note

References (8)

1. Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br j Haematol. 2004;12S:291 302.
2. Liebman HA. Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control. 2005;12; 11 -16.
3. Geerts WH,Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolvtic Therapy. Chest. 2004; 126:338-400.
4. Mandala M, Falanga A, Piccioli A, et al. Venous thromboembolism and cancer: guidelines of the Italian Association of.Medical Oncology (AIOM). Crit Rev Oncol 1 Hematol. 2006:59:194-204.
5. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors tor chemotherapy-associated venous thromboembolism in a prospective observ ational study. Cancer, 2006;l04:2822-2829.
6. McGinn TG, Guyatt GH, Wyer PC, et al. Users' guides to the medical literature. XXIL how to use articles about clinical decision rules. JAMA. 2000;284:79 84.
7. Altman DG, Royslon P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453 473.
8. Prandom P, Lexnsing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484 3488.